Next-Gen Primary Immunodeficiency Disorders : Market Forecast, Transformation, and Long-Term Trajectories
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Primary Immunodeficiency Disorders Market Expected to Grow Between 2025 And 2029?
The market size of primary immunodeficiency disorders has seen robust growth in the past few years. Market predictions indicate an escalation from $6.84 billion in 2024 to $7.3 billion in 2025, with a compound annual growth rate (CAGR) of 6.7%. The historical growth spurt can be credited to factors such as an increased prevalence of primary immunodeficiency disorders, improved awareness in the medical fraternity, a surge in demand for efficient treatment options, an upswing in research funding, and amplified attention on child healthcare.
The market size for primary immunodeficiency disorders is projected to observe notable enhancements in the coming years, growing to $9.43 billion in 2029 at a 6.6% compound annual growth rate (CAGR). This surge in the predicted period could be associated with an increasing uptake of subcutaneous therapies, better healthcare accessibility, strong research and development, an escalating need for effective treatments, and a growing demand for immunoglobulin replacement therapy. Key trends in this forecast period encompass developments in biotechnology, groundbreaking gene therapies and biologics, advancements in genetic testing and personalized medicine, progress in gene therapy, and improvements in genetic tests.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23483&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Primary Immunodeficiency Disorders Market?
The increasing occurrence of autoimmune diseases is anticipated to drive upward trends in the primary immunodeficiency disorders market. Autoimmune diseases arise when the immune system erroneously targets the body’s healthy cells and tissues, viewing them as invaders. This maladaptive response causes inflammation and damage across various organs and systems. The uptick in autoimmune diseases is linked to a nuanced combination of environmental factors, genetic susceptibility, and changes in lifestyle habits. Autoimmune diseases can result in primary immunodeficiency disorders through interference with immune regulation and targeting of immune cells, leading to compromised or impaired immune reactions. Take, for example, in November 2024, Versorgungsatlas.de, an interactive online platform based in Germany, reported that in 2022, out of 73,241,305 insured parties, a total of 6,304,340 were diagnosed with at least one autoimmune disease, yielding a raw prevalence rate of 8.61%. Thus, the escalating prevalence of autoimmune diseases is propelling the growth of the primary immunodeficiency disorders market.
Which Key Market Segments Comprise the Primary Immunodeficiency Disorders Market and Drive Its Revenue Growth?
The primary immunodeficiency disordersmarket covered in this report is segmented –
1) By Disease: Antibody Deficiency; Cellular Immunodeficiency; Innate Immune Disorders; Other Diseases
2) By Treatment: Immunoglobulin Replacement Therapy; Antibiotic Therapy; Stem Cell And Bone Marrow Transplantation; Gene Therapy; Other Treatments
3) By Diagnostic Type: Genetic Testing; Blood Testing; Flow Cytometry; Other Diagnostic Types
4) By End-User: Hospitals; Specialty Clinics; Homecare Settings; Research Institutions
Subsegments:
1) By Antibody Deficiency: Common Variable Immune Deficiency (CVID); IgA Deficiency; IgG Subclass Deficiency; Specific Antibody Deficiency
2) By Cellular Immunodeficiency: Severe Combined Immunodeficiency (SCID); T-Cell Deficiency; DiGeorge Syndrome; Wiskott-Aldrich Syndrome
3) By Innate Immune Disorders: Chronic Granulomatous Disease (CGD); Complement Deficiencies; Toll-like Receptor Deficiencies; Chediak-Higashi Syndrome
4) By Other Diseases: Hyper IgM Syndrome; Hyper IgE Syndrome; Ataxia-Telangiectasia; Combined Immunodeficiencies With Syndromic Features
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23483&type=smp
Which Areas Are Leading Regions in the Primary Immunodeficiency Disorders Market Expansion Across the Globe?
North America was the largest region in the primary immunodeficiency disorders market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary immunodeficiency disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in thePrimary Immunodeficiency Disorders Market Over the Coming Years?
Leading corporations in the primary immunodeficiency disorders market are concentrating their efforts on creating sophisticated therapies such as intravenous immunoglobulin therapy. This treatment strategy focuses on amplifying patient recovery by boosting immune functionality. This treatment incorporates the use of immunoglobulins or antibodies sourced from donor blood plasma, and is intravenously administered directly into the patient. For example, in June 2024, Grifols, a healthcare firm based in Spain, received FDA approval for Yimmugo, an intravenous immunoglobulin therapy. This innovative and sugar-free IgG solution, meant for intravenous use, is made from human blood plasma. Approved in the U.S for use as a substitution treatment for patients with primary antibody deficiency syndromes, Yimmugo provides replenishment of antibodies to aid those with immune deficiencies. This not only widens Grifols’ range of plasma-based treatments, but also adds a safer and more efficient option to safeguard against infections.
View the full report here:
How Is the Primary Immunodeficiency Disorders Market Conceptually Defined?
Primary immunodeficiency disorders (PIDs) are inherited conditions that weaken or impair the immune system, increasing vulnerability to infections, autoimmune diseases, and certain cancers. Identifying and diagnosing primary immunodeficiency disorders early is crucial for timely treatment, infection prevention, and enhancing patient well-being through therapies such as immunoglobulin replacement or bone marrow transplants.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23483
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
